TAU-Montefiore Medical Center-opioid use disorder-chronic pain

This refers to the Treatment As Usual (TAU) control arm of the clinical trial NCT05118204 (Micro-bupe) conducted by Montefiore Medical Center. The protocol involves a standard 2-day induction of buprenorphine-naloxone in hospitalized patients with chronic pain and opioid use disorder. Unlike the experimental microdose induction arm, the TAU protocol requires patients to stop all full mu-opioid agonists and enter a state of clinical opioid withdrawal before initiating treatment. The active pharmacological components are buprenorphine, a partial mu-opioid receptor agonist, and naloxone, a mu-opioid receptor antagonist included to deter parenteral misuse. The trial aims to compare the efficacy and tolerability of this standard approach against a novel low-dose induction method that allows for the continuation of full agonists during the transition period.

Brand names

Suboxone

Other names

Treatment As UsualStandard Buprenorphine Induction ProtocolTAU